Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan.
Three 10 micrograms of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in an adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/ l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects).
Costa
A A
AA
Serviço Especial de Saúde de Araraquara, São Paulo, Brasil.
Inenami
M
M
Juarez
E
E
Llacen
P D
PD
Raw
I
I
D000328:Adult; D006509:Hepatitis B / Q000517:prevention & control*; D017325:Hepatitis B Vaccines; D006801:Humans; D008875:Middle Aged; D014614:Vaccines, Synthetic; D015003:Yeasts
D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic